Table 1:

Pharmacologic interventions in asthma

Study	Population	Intervention	Comparator	Outcome	Timing	Setting	Results
Brown 2005²²	90 adults with asthma and major depressive disorder	12-week double-blind trial of citalopram	Placebo vs citalopram	Primary Outcome: HRSD, IDS-SR Secondary Outcomes^1: ACQ, AQLQ, corticosteroid use	Intervention: 12 weeks Outcomes Measured: Baseline, weeks 1, 2, 4, 6, 8 and 12	unspecified	Between group differences: No significant difference in HRDS, IDS-SR, ACQ at all timepoints measured. Significant difference in oral steroid use F1,273 6.26, (P=0.013) at all lime points measured and follow up assessments.
Brown 2018²³	139 adults with asthma and major depressive disorder	12-week, double-blind escitalopram (10mg/d) trial	Placebo vs escitalopram; high severity depression (HRSD score ≥ 20) vs low severity depression	Primary Outcomes: ACQ, HRSD, IDS-SR, corticosteroid use	Intervention: 12 weeks Outcomes Measured: Baseline, weeks 1 through 4 and then biweekly for weeks 6, 8, 10, and 12	unspecified	Between group differences: No statistically significant in ACQ, HRDS, or IDS-SR. Sub-analysis of higher severity of depression completers: - Change in ACQ between group difference t:t(19)= 2.27; P=.04; d=1.04 - Change in corticosteroid use between group difference: t(19)=2.18; P=0.04; d=1.00 - No statistically significant between group differences in HRSD or ISD-SR observed.
Brown 2012²⁴	26 adults with asthma and major depressive disorder	12-week double-blind escitalopram trial	Placebo vs escitalopram	Primary Outcome: ACQ, HAM-D, IDS-SR, oral prednisone use	Intervention: 12 weeks Outcomes Measured: Baseline, weeks 1 through 4 and then biweekly for weeks 6, 8, 10, and 12	unspecified	Between group differences: No significant change in HAM-D and IDS-SR. Combined total sample analysis: Significant change in HAM-D (t=0.38; P<0.01) and IDS-SR (t=0.49; P<0.01) between baseline and 12 weeks. ACQ correlated with IDS-SR: τ=0.49 – 0.60, P <0.05 in escitalopram, placebo, and combined sample. ACQ correlated with HAM-D in placebo and combined sample only (τ=0.38 – 0.58, P <0.05). No significant difference in oral prednisone use.

1 Secondary Outcomes include only psychosocial, asthma symptoms, and asthma quality of life measures

Hamilton Rating Scale for Depression (HAM-D-17); Hamilton Rating Scale for Anxiety (HAM-A), Hamilton Rating Scale for Depression (HRSD), Inventory of Depressive Symptomatology-Self Report (IDS-SR), Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ), Dyspnoea-12 (D-12), General Anxiety Disorder questionnaire (GAD-7), Patient Health Questionnaire (PHQ-9), State-Trait Anxiety Inventory (STAI score), Beck’s Depression Inventory (BDI), Beck’s Anxiety Inventory (BAI)